Study guide
13.4 Oncological Emergencies & Palliative Symptom Management
Professional and Linguistic Assessments Board Part 1 PLAB 1
Track your progress as you read
Finished sections get a check mark.
1 Introduction
About the PLAB 1 Exam
2 Chapter 1: Acute Medicine, Resuscitation & Clinical Emergencies
1.1 The ABCDE Approach, Adult Resuscitation & Shock 1.2 Sepsis, Sepsis Six Protocol & Septic Shock 1.3 Anaphylaxis & Acute Airway Emergencies 1.4 Clinical Toxicology & Acute Poisoning 1.5 Major Trauma, Head Injury, Burns & Environmental Emergencies
3 Chapter 2: Cardiovascular Medicine & Vascular Disorders
2.1 Acute Coronary Syndromes (STEMI & NSTEMI/Unstable Angina) 2.2 Heart Failure & Cardiogenic Shock 2.3 Cardiac Arrhythmias & Syncope 2.4 Hypertension, Valvular Heart Disease & Aortic Emergencies 2.5 Infective Endocarditis, Pericardial Disease, Myocarditis & Cardiomyopathies 2.6 Peripheral Arterial Disease, Aortic Aneurysm & Venous Disease
4 Chapter 3: Respiratory Medicine
3.1 Asthma: Diagnostic Criteria, Chronic Stepping & Acute Exacerbations 3.2 COPD: Staging, Long-Term Management & Acute Exacerbations 3.3 Pneumonia & Lower Respiratory Tract Infections 3.4 Venous Thromboembolism, Pleural Disease & Pneumothorax 3.5 Lung Cancer, Interstitial & Suppurative Lung Disease, Sleep Apnoea & Respiratory Failure
5 Chapter 4: Gastroenterology, Hepatobiliary & General Surgery
4.1 Upper Gastrointestinal Bleeding & Dyspepsia 4.2 Lower Gastrointestinal Bleeding, IBD & Colorectal Malignancy 4.3 Acute Abdomen, Bowel Obstruction & Perforation 4.4 Hepatobiliary Disease, Cirrhosis & Acute Pancreatitis 4.5 Functional, Malabsorptive & Infective Bowel Disorders, Anorectal Disease, Hernias & MASLD
6 Chapter 5: Renal Medicine, Urology & Fluid/Electrolyte Balance
5.1 Acute Kidney Injury & KDIGO Staging 5.2 Chronic Kidney Disease & Glomerular Disorders 5.3 Electrolyte Emergencies: Potassium, Sodium & Calcium 5.4 Urology: Urinary Tract Infections, Renal Colic & Urinary Retention 5.5 Urological Cancers, Prostate Disease & Scrotal Emergencies
7 Chapter 6: Endocrinology & Metabolic Medicine
6.1 Diabetes Mellitus: Diagnostic Criteria & Chronic Management 6.2 Diabetic Emergencies: DKA & Hyperosmolar Hyperglycaemic State 6.3 Thyroid Disorders: Hypothyroidism, Thyrotoxicosis & Thyroid Storm 6.4 Adrenal & Pituitary Disorders: Addisonian Crisis & Pituitary Disease
8 Chapter 7: Neurology & Neurosciences
7.1 Acute Stroke, TIA & Intracranial Haemorrhage 7.2 Acute & Chronic Headaches, Giant Cell Arteritis & CNS Infections 7.3 Seizures, Status Epilepticus & Epilepsy Management 7.4 Neuromuscular Disorders & Movement Disorders 7.5 Raised Intracranial Pressure, Brain Tumours, Cranial Nerve Lesions & Spinal Cord Disorders
9 Chapter 8: Psychiatry & Mental Health
8.1 Affective Disorders: Depression, Bipolar Disorder & Suicide Risk Assessment 8.2 Psychosis, Schizophrenia & Acute Agitation 8.3 Cognitive Disorders, Substance Misuse & the Mental Health Act 8.4 Anxiety Disorders, OCD, PTSD, Eating Disorders, Personality Disorders & Somatic Presentations 8.5 Perinatal, Child & Adolescent and Neurodevelopmental Mental Health
10 Chapter 9: Obstetrics, Gynaecology & Sexual Health
9.1 Early Pregnancy: Miscarriage & Ectopic Pregnancy 9.2 Antenatal & Peripartum Emergencies: Pre-Eclampsia & Haemorrhage 9.3 Common Gynaecological Presentations & Gynaecological Oncology 9.4 Contraception, Emergency Contraception & Sexually Transmitted Infections 9.5 Routine Antenatal Care, Labour & Obstetric Emergencies 9.6 Menopause & HRT, Subfertility, Prolapse & Urinary Incontinence
11 Chapter 10: Paediatrics & Child Health
10.1 The Febrile Child, Sepsis & Meningococcal Disease 10.2 Paediatric Respiratory Distress: Croup, Bronchiolitis & Wheeze 10.3 Paediatric Abdominal Emergencies, Dehydration & Neonatal Jaundice 10.4 Child Safeguarding, Non-Accidental Injury & Developmental Milestones 10.5 Neonatology & Congenital Heart Disease 10.6 Paediatric Orthopaedics, Growth, Childhood Cancer & Common Chronic Problems
12 Chapter 11: Musculoskeletal Medicine & Rheumatology
11.1 Inflammatory Arthropathies & Connective Tissue Diseases 11.2 Crystal Arthropathies (Gout & Pseudogout) & Septic Arthritis 11.3 Osteoporosis, Common Fractures & Orthopaedic Emergencies 11.4 Osteoarthritis, Low Back Pain, Polymyalgia Rheumatica, Fibromyalgia & Soft Tissue Disorders
13 Chapter 12: Dermatology, ENT & Ophthalmology
12.1 Common Dermatoses & Dermatological Emergencies 12.2 ENT Presentations: Infections, Epistaxis, Vertigo, Hearing Loss & Head and Neck Lumps 12.3 The Acute Red Eye: Glaucoma, Uveitis & Keratitis 12.4 Sudden & Gradual Vision Loss, Retinal Disorders & the Visual Pathway 12.5 Skin Infections, Infestations, Childhood Rashes & Skin Cancer
14 Chapter 13: Haematology, Oncology & Palliative Care
13.1 Anaemias & Blood Transfusion Medicine 13.2 Haematological Malignancies: Leukaemias, Lymphomas & Myeloma 13.3 Haemostasis, Coagulation Disorders & Anticoagulant Reversal 13.4 Oncological Emergencies & Palliative Symptom Management 13.5 Breast Disease, Cancer Screening & Suspected Cancer Referral
15 Chapter 14: Perioperative Care, Safe Prescribing & Clinical Pharmacology
14.1 Preoperative Assessment & Perioperative Medication Management 14.2 Postoperative Complications & Fluid Therapy 14.3 High-Risk Medications & Therapeutic Drug Monitoring 14.4 Safe Prescribing Principles & Antimicrobial Stewardship
16 Chapter 15: Medical Ethics, Law & UK Clinical Practice
15.1 GMC Good Medical Practice, Professionalism, Teamwork & Quality Improvement 15.2 Consent, Capacity & the Mental Capacity Act 2005 15.3 Confidentiality, Statutory Reporting & DVLA Regulations 15.4 End-of-Life Decisions, DNACPR, Organ Donation, Adult Safeguarding & Domestic Abuse
17 Chapter 16: Infectious Diseases, Travel Medicine & Infection Prevention
16.1 Tuberculosis, HIV, Hepatitis B & C and Needlestick Injuries 16.2 Fever in the Returning Traveller, Zoonoses, Notifiable Diseases & Infection Prevention
18 Chapter 17: Older Adults, Population Health, Genetics & Clinical Imaging
17.1 Frailty, Falls, Polypharmacy, Continence & Pressure Ulcers 17.2 Medical Statistics, Diagnostic Tests & Critical Appraisal 17.3 Public Health, Screening Principles, Health Inequalities & Health Promotion 17.4 Genetics, Genomics & Pharmacogenomics 17.5 Clinical Imaging: Choosing Tests, Radiation Safety & Interpreting X-rays
13.4 Oncological Emergencies & Palliative Symptom Management
Key Takeaways Explain This Topic AI
Metastatic Spinal Cord Compression (MSCC) is an acute neurological emergency requiring immediate oral Dexamethasone (16 mg stat with PPI cover) and emergency whole-spine MRI within 24 hours.
Neutropenic sepsis is a medical emergency with a strict door-to-needle time of <1 hour for broad-spectrum antipseudomonal beta-lactams (IV Piperacillin-tazobactam 4.5 g TDS); antibiotics must never be delayed for blood cultures.
Hypercalcaemia of malignancy is treated initially with aggressive IV 0.9% normal saline rehydration (3–4 L/24h) followed by IV bisphosphonates (Zoledronic acid 4 mg); loop diuretics are reserved only for fluid overload.
In palliative opioid prescribing, the breakthrough pain dose is 1/10 to 1/6 of the total 24-hour regular opioid dose (commonly 1/6); oral morphine converts to subcutaneous morphine by dividing by 2, and to subcutaneous diamorphine by dividing by 3.
Last updated: October 2026
Oncological Emergencies & Palliative Symptom Management
Oncological emergencies are acute, life-threatening complications arising directly from tumor expansion, metabolic dysregulation, or antineoplastic therapy. Palliative medicine provides active, holistic symptom control for advanced progressive malignancy and terminal end-of-life care.
- 1. Oncological Emergencies
- 1. Metastatic Spinal Cord Compression (MSCC)
MSCC occurs in ~5% of all cancer patients, most frequently secondary to osteolytic vertebral metastases from prostate, breast, and lung cancers , followed by renal cell carcinoma, lymphoma, and myeloma. The thoracic spine is the most common anatomical site (~70%), followed by the lumbosacral (~20%) and cervical (~10%) spine.
Clinical Presentation:
Early Warning Sign: Severe, localized, progressive spinal back pain, characteristically worse when lying flat, coughing, straining, or weight-bearing , often disturbing sleep.
Radicular Pain: Band-like dermatomal pain radiating around the chest wall or down the limbs.
Neurological Signs: Bilateral lower limb motor weakness, hyperreflexia, extensor plantar responses (Babinski sign), and a definitive sensory level .
Autonomic Dysfunction (Late Sign): Urinary retention with overflow incontinence, faecal incontinence, or reduced anal sphincter tone. Once sphincter control is lost, the likelihood of regaining ambulation drops drastically.
Emergency Management Protocol (NICE NG234, 2023, which replaced CG75):
Immediate High-Dose Corticosteroids: Administer oral Dexamethasone 16 mg stat immediately (with oral proton pump inhibitor gastroprotection, e.g. omeprazole 20 mg), followed by 8 mg twice daily. Dexamethasone rapidly reduces vasogenic cord oedema and retards neurological compromise.
Emergency Whole-Spine MRI: Perform an urgent MRI of the entire spine within 24 hours (or within a few hours if progressive motor weakness or sphincter dysfunction is present). Imaging must cover the cervical, thoracic, and lumbar spine because multiple non-contiguous metastases are present in >30% of patients.
Emergency Decompression: Urgent contact with the local MSCC coordinator and spinal surgical team for emergency surgical decompression and stabilization (preferred in solitary metastases with spinal instability), or emergency external beam radiotherapy within 24 hours.
2. Superior Vena Cava Obstruction (SVCO)
Extrinsic compression or secondary intraluminal thrombosis of the thin-walled Superior Vena Cava within the rigid middle mediastinum. Most commonly caused by small cell lung cancer (SCLC) , non-small cell lung cancer, and high-grade non-Hodgkin lymphoma.
Clinical Presentation: Dyspnoea (most common), facial swelling, periorbital puffiness, bilateral arm oedema, headache and dizziness (worse upon bending forward), and distended, non-pulsatile collateral veins over the anterior chest wall and neck. Pemberton's sign is positive (raising both arms above the head for 1 minute precipitates facial plethora, cyanosis, and respiratory distress).
Emergency Management:
Sit the patient upright and deliver supplemental high-flow oxygen.
Administer oral Dexamethasone 16 mg daily (with PPI cover) to reduce peritumoral mediastinal oedema.
Urgent contrast-enhanced CT thorax to determine anatomical site and vascular patency.
Definitive relief: Endovascular SVC stenting provides rapid symptomatic relief (>90% within 24–48 hours), followed by histological confirmation and urgent chemotherapy (for SCLC / lymphoma) or radiotherapy.
3. Neutropenic Sepsis
Definition (NICE CG151): An absolute neutrophil count <0.5 x 10^9/L (or <1.0 x 10^9/L and rapidly falling) in a patient undergoing systemic antineoplastic chemotherapy, PLUS either:
A temperature >38.0°C , OR
Any symptoms or clinical signs consistent with systemic sepsis (hypotension, tachycardia, rigors, hypothermia <36.0°C).
Door-to-Needle Mandate: Door-to-needle time must be <1 hour from initial presentation to the delivery of the first dose of intravenous antipseudomonal broad-spectrum monotherapy.
Empirical Antibiotic Protocol: Intravenous Piperacillin-tazobactam (Tazocin) 4.5 g every 8 hours . If the patient has a severe penicillin allergy, administer IV Meropenem (or Ciprofloxacin plus Vancomycin).
Warning
Never Delay Antibiotics: Diagnostic investigations (blood cultures, chest radiograph, urine microscopy, venous line swabs) must be obtained rapidly, but intravenous antibiotics must never be withheld or delayed awaiting test results. Every hour of delay increases mortality significantly.
4. Hypercalcaemia of Malignancy
Occurs in up to 30% of advanced cancers, driven by tumor secretion of Parathyroid Hormone-related Protein (PTHrP) (squamous cell carcinomas of lung, head, neck, oesophagus) or osteolytic bone metastases (breast, myeloma).
Clinical Presentation: "Stones, bones, abdominal groans, and psychic moans"—fatigue, anorexia, severe nausea, intractable constipation, polyuria, polydipsia, cognitive slowing, confusion, and shortened QT interval on ECG. Severe when corrected serum calcium exceeds 3.0 mmol/L .
Emergency Management Protocol:
Aggressive Intravenous Hydration: Patients are profoundly volume-depleted from nephrogenic diabetes insipidus. Infuse IV 0.9% normal saline at 3–4 litres over the first 24 hours to restore intravascular volume and promote renal calciuria.
Intravenous Bisphosphonates: Once rehydrated, administer Zoledronic acid 4 mg IV infusion over 15 minutes (or Pamidronate 60–90 mg). Bisphosphonates inhibit osteoclastic bone resorption; maximal normocalcaemic effect occurs at 48–72 hours .
Loop Diuretics Caution: Furosemide is strictly contraindicated during initial resuscitation ; it is reserved exclusively for patients who develop fluid overload following aggressive rehydration.
Refractory Cases: Denosumab (monoclonal antibody targeting RANKL) is effective in bisphosphonate-refractory hypercalcaemia or severe renal impairment.
5. Tumour Lysis Syndrome (TLS)
Massive, spontaneous or chemotherapy-induced necrosis of rapidly dividing hematological malignancies (Burkitt lymphoma, ALL, AML).
Cairo-Bishop Laboratory Criteria (≥2 of the following within 3–7 days of chemotherapy):
- Hyperkalaemia: K+ >6.0 mmol/L (risk of fatal ventricular arrhythmias)
- Hyperphosphataemia: PO4 >1.45 mmol/L (precipitates with calcium)
- Hypocalcaemia: Corrected Ca <1.75 mmol/L (tetany, seizures, QT prolongation)
- Hyperuricaemia: Uric acid >475 umol/L (precipitates in renal tubules causing AKI)
Prophylaxis & Therapy:
Vigorous IV hydration (3 L/m^2/day).
Rasburicase (recombinant urate oxidase): Converts poorly soluble uric acid directly into highly soluble allantoin , rapidly lowering uric acid within 4 hours. Absolute Contraindication: G6PD deficiency (the enzymatic breakdown generates hydrogen peroxide, triggering severe methaemoglobinaemia and haemolysis).
Allopurinol: Competitive xanthine oxidase inhibitor used for low/intermediate risk TLS prophylaxis (prevents new uric acid formation but does not degrade existing uric acid).
Oncological Emergency Cardinal Symptoms / Signs First-Line Emergency Medical Action
MSCC Progressive back pain worse flat, motor weakness, sensory level Oral Dexamethasone 16 mg stat + whole-spine MRI within 24h
SVCO Facial/arm oedema, dyspnoea, dilated non-pulsatile chest veins Sit upright, oxygen, Dexamethasone 16 mg , urgent CT thorax
Neutropenic Sepsis Neutrophils <0.5 x 10^9/L, temp >38°C or septic signs IV Piperacillin-tazobactam 4.5 g within <1 hour of arrival
Hypercalcaemia Polyuria, polydipsia, nausea, confusion, Ca >3.0 mmol/L IV 0.9% saline 3–4 L/24h , followed by IV Zoledronic acid 4 mg
Tumour Lysis (TLS) High K, high PO4, high uric acid, low Ca; rising creatinine Vigorous IV hydration + IV Rasburicase (or Allopurinol)
- 2. Palliative Medicine & End-of-Life Symptom Management
- The WHO Analgesic Ladder
Step 1 (Mild Pain): Non-opioid analgesics: Paracetamol (1 g QDS) +/- Non-Steroidal Anti-inflammatory Drugs ( NSAIDs , e.g. Ibuprofen or Naproxen, adding PPI cover).
Step 2 (Moderate Pain): Weak opioid combined with Step 1 non-opioids: Codeine phosphate (30–60 mg QDS), Dihydrocodeine , or Tramadol (50–100 mg QDS).
Step 3 (Severe Pain): Strong opioids: Morphine sulfate , Oxycodone , or transdermal Fentanyl / Buprenorphine .
Strong Opioid Prescribing & Conversions
Initiating Strong Opioids: In an opioid-naive patient, start with immediate-release oral morphine (e.g. Oramorph 5–10 mg every 4 hours PRN) or convert to modified-release (MR) morphine (e.g. MST Continus 10–20 mg BD). Co-prescribe a stimulant laxative (e.g. Senna) and an antiemetic (e.g. Haloperidol or Metoclopramide) routinely.
Breakthrough Pain Calculation: The breakthrough pain dose is usually one-tenth to one-sixth (1/10 to 1/6) of the total 24-hour regular background opioid dose (1/6 is the figure most often used in UK teaching), administered as immediate-release morphine PRN (can be given every 2–4 hours).
Standard Opioid Conversion Factors:
Oral Morphine to Subcutaneous (SC) Morphine: Divide total oral 24-hour dose by 2 (Ratio 2:1).
Oral Morphine to Subcutaneous (SC) Diamorphine: Divide total oral 24-hour dose by 3 (Ratio 3:1).
Oral Codeine / Tramadol to Oral Morphine: Divide total oral 24-hour dose by 10 (Ratio 10:1).
Oral Morphine to Oral Oxycodone: Divide total oral morphine dose by 1.5 to 2 (used when morphine causes intractable neurotoxicity / hallucinations).
Continuous Subcutaneous Infusion (CSCI) Syringe Drivers
When patients enter the terminal phase and lose the ability to swallow oral medications reliably, essential symptom-control medications are combined in a continuous subcutaneous syringe driver over 24 hours:
Pain: Continuous subcutaneous infusion of Morphine or Diamorphine .
Breathlessness (Dyspnoea): Low-dose subcutaneous Morphine (relieves the sensation of air hunger by blunting brainstem respiratory drive perception) combined with low-dose subcutaneous Midazolam (relieves panic and anxiety).
Nausea & Vomiting: Antiemetic selected according to underlying pathophysiology:
Chemical / Metabolic / Opioid-Induced (CTZ D2-mediated): Haloperidol (1.5–3 mg/24h SC) or Metoclopramide (30–60 mg/24h SC; prokinetic, avoid in mechanical bowel obstruction).
Mechanical Bowel Obstruction / Raised ICP / Vestibular: Cyclizine (150 mg/24h SC; antihistaminic and antimuscarinic).
Broad-Spectrum / Refractory Nausea: Levomepromazine (6.25–25 mg/24h SC; blocks dopamine, histamine, and 5-HT receptors).
Terminal Respiratory Secretions ("Death Rattle"): Caused by pooled secretions in the hypopharynx in comatose, dying patients unable to cough or clear the airway. Start early before fluid accumulates. First-line: subcutaneous antimuscarinics— Glycopyrronium bromide (200 mcg SC stat PRN or 600–1200 mcg/24h infusion; does not cross the blood-brain barrier, minimizing central sedation/delirium) or Hyoscine butylbromide (Buscopan) (20 mg SC stat PRN or 60–120 mg/24h infusion). Reposition the patient semi-prone or on their side; avoid distressful suctioning.
Terminal Agitation & Restlessness: First-line: subcutaneous Midazolam (2.5–5 mg SC stat PRN, or 10–30 mg/24h continuous infusion). For severe delirium or hallucinations: add Levomepromazine or Haloperidol .